| EPB0267 | Factors associated with viral load suppression amongst transgender people in South Africa | E-poster | Clinical issues specific to key populations |
| EPB0266 | Mpox knowledge, concern, willingness to change behaviour, and seek vaccination in Australia: results of a national cross-sectional survey | E-poster | Clinical issues specific to key populations |
| EPB0265 | Evaluating the perceptions of PWID about long-acting MOUD, PrEP, and ART | E-poster | Clinical issues specific to key populations |
| EPB0264 | Oropharyngeal presentation of mpox: a neglected entity? | E-poster | Clinical issues specific to key populations |
| EPB0263 | Single cell rnaseq analysis of persons with HIV and opioid use | E-poster | Clinical issues specific to key populations |
| EPB0262 | Impact of a teen club model on improving HIV outcomes among adolescents in rural Neno district, Malawi: a retrospective cohort study | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| EPB0261 | Implementation of a Quality Improvement collaborative of HIV status disclosure of Young People Living with HIV in Zimbabwe | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| EPB0260 | HIV drug resistance trends among 251 treatment experienced children and young adults (0-24 years) | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| EPB0259 | Outcomes from the Transitioning children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) study at 6 months in Benin, Nigeria, and Uganda | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| EPB0258 | High acceptability and preference for pediatric dolutegravir 10mg among children living with HIV in Nigeria at 1- and 6-month follow up, an observational study | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |